Characteristics of the 5 patients with refractory disease included in this study
| Patient . | Sex . | Age (y) . | Clinical status at time of drug profiling . | Salvage treatment . | Current status . |
|---|---|---|---|---|---|
| 1 | F | 2 | Relapsed after SCT, early relapse | MLL:MLLT10-positive; blinatumomab | Alive, follow-up at 15 mo |
| 2 | M | 7 | Relapsed after SCT, second relapse, resistant to anti-CD19 therapy | Blinatumomab, second transplant | Alive, follow-up at 9 mo |
| 3 | F | 8 | Relapsed after SCT, second relapse | Chemotherapy, second transplant | Died |
| 4 | F | 5 | Very early BM relapse | Resistant to blinatumomab, no response to bortezomib combined with 4 drugs | Died |
| 5 | F | 11 | Relapsed after SCT, second (late) relapse | Second transplant, resistant to blinatumomab, partial response to bortezomib combined with 4 drugs | Died |
| Patient . | Sex . | Age (y) . | Clinical status at time of drug profiling . | Salvage treatment . | Current status . |
|---|---|---|---|---|---|
| 1 | F | 2 | Relapsed after SCT, early relapse | MLL:MLLT10-positive; blinatumomab | Alive, follow-up at 15 mo |
| 2 | M | 7 | Relapsed after SCT, second relapse, resistant to anti-CD19 therapy | Blinatumomab, second transplant | Alive, follow-up at 9 mo |
| 3 | F | 8 | Relapsed after SCT, second relapse | Chemotherapy, second transplant | Died |
| 4 | F | 5 | Very early BM relapse | Resistant to blinatumomab, no response to bortezomib combined with 4 drugs | Died |
| 5 | F | 11 | Relapsed after SCT, second (late) relapse | Second transplant, resistant to blinatumomab, partial response to bortezomib combined with 4 drugs | Died |
BM, bone marrow; F, female; M, male; SCT, stem cell transplant.